

The authors reply:

Letter on: “Pitfalls in the measurement of muscle mass: a need for a reference standard” by Clark et al.

Abstract

However, semantics aside, we think that DXA can indeed serve as a reference standard for measuring muscle mass. Obviously, CT and MRI are advanced techniques that can and have been used to obtain important information such as muscle size/volume and more recently amount and distribution of intra- and intermuscular adipose tissue. Also individual muscles can be assessed separately. However, with respect to muscle mass, the comparison of DXA with CT/MRI is rather difficult because DXA and QCT/MRI measure different physical parameters

Keywords Lean body mass; Lean mass; Muscle mass; Reference standard

Received: 24 July 2018; Accepted: 27 November 2018

We very much appreciate your valuable comments and your interest in the topic raised in our paper.¹ One of your main concerns seem to be the statement at the end of our contribution suggesting that ‘DXA is the gold standard for the measurement of muscle mass’. Perhaps the term ‘gold’ could have been omitted. However, semantics aside, we think that DXA can indeed serve as a reference standard for measuring muscle mass as concluded in the discussion and summarized in the abstract. Obviously, CT and MRI are advanced techniques that can and have been used to obtain important information such as muscle size/volume and more recently amount and distribution of intramuscular and intermuscular adipose tissue.^{2,3} Also, individual muscles can be assessed separately. However, with respect to muscle mass, the comparison of DXA with CT/MRI is rather difficult because DXA and QCT/MRI measure different physical parameters.

As you correctly describe, primary outcome of DXA is lean mass in g, of CT is muscle volume in cm³ or area in cm² and CT density in Hounsfield units [HU] and of MRI is also muscle volume in cm³ or area and proton density fat and water fraction in % when using advanced Dixon sequences.⁴ None of the three techniques measures muscle mass in g or muscle density in g/cm³. CT and MRI do not even directly measure a mass in g. Thus, from a physics point of view, none can serve as a gold standard for any of the other two methods, with the exception of volume/area measurements of CT and MRI.

For the further discussion, it is important to remember that all current definitions of sarcopenia include appendicular

lean mass but not muscle area/volume.^{5,6} You refer to accuracy validation studies with MR and CT^{7–10} but all evaluated area, not mass. Correlations reported between DXA lean mass and CT muscle area in the thigh were moderate in young subjects ($r^2 = 0.74$)¹¹ and even lower in premenopausal lean and obese women ($r^2 = 0.59$ and $r^2 = 0.58$, respectively),¹² thus a substitution of DXA by CT in the definition of sarcopenia, i.e. of mass by volume, will be problematic.

There are indeed some studies that report muscle mass from CT and MRI scans.^{13–15} In these studies, muscle mass has been estimated by multiplying measured muscle volume with a density of 1.06 or 1.04 g/cm³, values based on publications summarized in the ICRP reference man report from 1972.¹⁶ In this report, the proportion of fat of wet skeletal muscle in adults is given as a range from 2.2% to 9.4%. Thus, accuracy of assuming a muscle density of 1.06 or 1.04 g/cm³ is questionable if higher degrees of muscle fat infiltration occur, because higher proportions of fat will decrease density. Correlation coefficients of $r^2 \geq 0.96$ have been reported in young and elderly healthy volunteers^{11,15} between muscle mass in the thigh estimated with CT and fat free mass (FFM) measured by DXA but results are likely to change in subjects with a higher amount of intramuscular adipose tissue of let's say greater than 10%. Thus, these studies for a specific population serve more as a validation of the simplifying assumptions made to obtain CT/MRI muscle mass than a validation for DXA.

Finally, you point out only moderate correlations between longitudinal changes in lean mass and muscle volume. But with the current definitions of sarcopenia,

wouldn't this be an argument in favour of DXA? One could criticize that definitions of sarcopenia inherently favour DXA and should have been better tailored towards CT or MR measurements in the first place. They even use appendicular lean instead of muscle mass,¹⁷ which has been rightfully criticized. However, the real problem is the rather poor correlation of the common DXA/CT/MRI measurements with function, which has caused the integration of functional measurements in the definitions of sarcopenia. Thus, we do not imply that DXA will be the gold standard for the diagnosis of sarcopenia, which requires a functional component. However, DXA can serve as a reference standard for lean mass, considering the limitations described in our article.¹⁸ Similar to osteoporosis, DXA may become the workhorse in clinical routine of sarcopenia. CT and MRI should be regarded as a complementary more powerful imaging method to DXA that may improve our understanding on intervention and may eventually better explain effects on functional muscle outcome than simple lean mass or area/volume measurements.

Acknowledgement

The authors certify that they comply with the ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2017.¹⁹

Fanny Buckinx

*Department of Public Health, Epidemiology and Health Economics,
University of Liège, Liège, Belgium*

Francesco Landi

*Department of Geriatrics, Neurosciences and Orthopedics, Catholic University
of the Sacred Heart Rome, Milan, Italy*

Matteo Cesari

*Gérontopôle, University Hospital of Toulouse, Toulouse, France
INSERM UMR1027, University of Toulouse III Paul Sabatier, Toulouse, France*

Roger A. Fieding

*Nutrition, Exercise Physiology and Sarcopenia Laboratory, Jean Mayer USDA
Human Nutrition Research Center on Aging at Tufts University, Boston,
MA, USA*

Marjolein Visser

*Department of Health Sciences, VU University Amsterdam, Amsterdam,
Netherlands
Department of Nutrition and Dietetics, Internal Medicine, VU University
Medical Center, Amsterdam, Netherlands*

Klaus Engelke

Institute of Medical Physics, University of Erlangen, Erlangen, Germany

Stefania Maggi

National Research Council, Neuroscience Institute, Aging Branch, Padova, Italy

Elaine Dennison

*MRC Lifecourse Epidemiology Unit, University of Southampton,
Southampton, UK*

Nasser M. Al-Daghri

*Prince Mutaib Chair for Biomarkers of Osteoporosis, Biochemistry Department,
College of Science, King Saud University, Riyadh 11451, Saudi Arabia*

Sophie Allepaerts

Department of Geriatrics, CHU-Liège, Liège, Belgium

Jurgen Bauer

*Department of Geriatric Medicine, Klinikum, Carl von Ossietzky University,
Oldenburg, Germany*

Ivan Bautmans

*Gerontology and Frailty in Ageing Research Department, Vrije Universiteit
Brussel (VUB), Brussels, Belgium*

Maria-Luisa Brandi

*Department of Surgery and Translational Medicine, University of Florence,
Florence 59139, Italy*

Olivier Bruyère

*Department of Public Health, Epidemiology and Health Economics,
University of Liège, Liège, Belgium*

Tommy Cederholm

*Human Medicines Research and Development Support Division, Scientific
Advice, London, UK*

Francesca Cerreta

*Human Medicines Research and Development Support Division, Scientific
Advice, London, UK*

Antonio Cherubini

Geriatrics and Geriatric Emergency Care, IRCCS-INRCA, Ancona, Italy

Cyrus Cooper

*MRC Lifecourse Epidemiology Unit, University of Southampton,
Southampton, UK
NIHR Musculoskeletal Biomedical Research Unit, University of Oxford,
Oxford, UK*

Alphonso Cruz-Jentoft

*Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de
Investigación Sanitaria (Irycis), Madrid, Spain*

Eugene McCloskey

*Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK
MRC and Arthritis Research UK Centre for Integrated research in Musculo-
skeletal Ageing (CIMA), London, UK*

Bess Dawson-Hughes

Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA

National Institute for Health Research Southampton Biomedical Research Centre, University of Southampton and University Hospital, Southampton NHS Foundation Trust, Southampton, UK

Jean-Marc Kaufman

Department of Endocrinology and Unit for Osteoporosis and Metabolic Bone Diseases, Ghent University Hospital, Ghent, Belgium

Yves Rolland
Gérontopôle de Toulouse, Institut du Vieillissement, Centre Hospitalo-Universitaire de Toulouse (CHU Toulouse); UMR INSERM 1027, University of Toulouse III, Toulouse, France

Andrea Laslop

Scientific Office, Austrian Agency for Health and Food Safety, Vienna, Austria

Jean Petermans

Department of Geriatrics, CHU-Liège, Liège, Belgium

Jean-Yves Reginster

Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium

René Rizzoli

Service of Bone Diseases, Department of Internal Medicine Specialties, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland

John A. Kanis
Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK
Institute of Health and Ageing, Australian Catholic University, Melbourne, Australia

Sian Robinson

MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK

References

- Buckinx F, Landi F, Cesari M, Fielding RA, Visser M, Engelke K, et al. Pitfalls in the measurement of muscle mass: a need for a reference standard. *J Cachexia Sarcopenia Muscle* 2018;**9**:269–278.
- Heymsfield SB, Adamek M, Gonzalez MC, Jia G, Thomas DM. Assessing skeletal muscle mass: historical overview and state of the art. *J Cachexia Sarcopenia Muscle* 2014;**5**:9–18.
- Muhlberg A, Museyko O, Laredo JD, Engelke K. A reproducible semi-automatic method to quantify the muscle-lipid distribution in clinical 3D CT images of the thigh. *PLoS One* 2017;**12**:e0175174.
- Grimm A, Meyer H, Nickel MD, Nittka M, Raithel E, Chaudry O, et al. A comparison between 6-point Dixon MRI and mr spectroscopy to quantify muscle fat in the thigh of subjects with sarcopenia. *JFA* 2018; online.
- Dawson-Hughes B, Bischoff-Ferrari H. Considerations concerning the definition of sarcopenia. *Osteoporos Int* 2016;**27**:3139–3144.
- Marzetti E, Calvani R, Tosato M, Cesari M, Di Bari M, Cherubini A, et al. Sarcopenia: an overview. *Aging Clin Exp Res* 2017;**29**:11–17.
- Mitsiopoulos N, Baumgartner RN, Heymsfield SB, Lyons W, Gallagher D, Ross R. Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. *J Appl Physiol* (1985) 1998;**85**:115–122.
- Engstrom CM, Frupp J, Jurcak V, Walker DG, Salvado O, Crozier S. Segmentation of the quadratus lumborum muscle using statistical shape modeling. *J Magn Reson Imaging* 2011;**33**:1422–1429.
- Morse CI, Degens H, Jones DA. The validity of estimating quadriceps volume from single MRI cross-sections in young men. *Eur J Appl Physiol* 2007;**100**:267–274.
- Gacesa JZ, Klasnja AV, Grujic NG. Changes in strength, endurance, and fatigue during a resistance-training program for the triceps brachii muscle. *J Athl Train* 2013;**48**:804–809.
- Levine JA, Abboud L, Barry M, Reed JE, Sheedy PF, Jensen MD. Measuring leg muscle and fat mass in humans: comparison of CT and dual-energy X-ray absorptiometry. *J Appl Physiol* (1985) 2000;**88**:452–456.
- Bredella MA, Ghomi RH, Thomas BJ, Torriani M, Brick DJ, Gerweck AV, et al. Comparison of DXA and CT in the assessment of body composition in premenopausal women with obesity and anorexia nervosa. *Obesity (Silver Spring)* 2010;**18**:2227–2233.
- Kim J, Wang Z, Heymsfield SB, Baumgartner RN, Gallagher D. Total-body skeletal muscle mass: estimation by a new dual-energy X-ray absorptiometry method. *Am J Clin Nutr* 2002;**76**:378–383.
- Lonn L, Kvist H, Ernest I, Sjöström L. Changes in body composition and adipose tissue distribution after treatment of women with Cushing's syndrome. *Metabolism* 1994;**43**:1517–1522.
- Visser M, Fuerst T, Lang T, Salamone L, Harris TB, For The Health, et al. Validity of fan-beam dual-energy X-ray absorptiometry for measuring fat-free mass and leg muscle mass. Health, aging, and body composition study—dual-energy X-ray absorptiometry and body composition working group. *J Appl Physiol* (1985) 1999;**87**:1513–1520.
- ICRP, Publication 23. Report of the task group on reference man. In *International Commission on Radiological Protection*. Oxford: Pergamon Press; 1975. p 1975.
- Reginster JY, Cooper C, Rizzoli R, Kanis JA, Appelboom G, Bautmans I, et al. Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia. *Aging Clin Exp Res* 2016;**28**:47–58.
- Guglielmi G, Ponti F, Agostini M, Amadori M, Battista G, Bazzocchi A. The role of DXA in sarcopenia. *Aging Clin Exp Res* 2016;**28**:1047–1060.
- von Haehling S, Morley JE, Coats AJ, Anker SD. Ethical guidelines for publishing in the journal of cachexia, sarcopenia and muscle: update 2017. *J Cachexia Sarcopenia Muscle* 2017;**8**:1081–1083.